Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary.
07.06.2024 - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with .
Monashee Investment Management LLC lessened its stake in Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) by 34.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,459,854 shares of the company’s stock after selling 1,844,358 shares during the period. Gossamer Bio […]
Gossamer, Chiesi Ink $486M Collab Deal - San Diego Business Journal sdbj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sdbj.com Daily Mail and Mail on Sunday newspapers.